Marsha A. Raebel, PharmD

Emeritus Senior Investigator

Marsha A. Raebel, PharmD, is an Emeritus Senior Investigator at the Institute for Health Research. Her research focuses on medication safety, medication adherence, and pharmacoepidemiology, with an emphasis on adverse drug event surveillance and reducing medication and laboratory monitoring errors in the outpatient setting.

Dr. Raebel completed her doctoral training in pharmacotherapy at the University of Texas Health Sciences Center at San Antonio and the University of Texas at Austin College of Pharmacy. She is nationally-recognized for her foundational research in medication adherence and safety, diabetes, clinical pharmacy, and clinical decision support. She is an investigator for the U.S. Food and Drug Administration (FDA) Sentinel initiative and an investigator in the FDA-sponsored Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) project.

Dr. Raebel is a Clinical Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and a Fellow of the American College of Clinical Pharmacy.

Selected Research:

  • Management of Direct Oral Anticoagulants to Lower Adverse Events in Atrial Fibrillation (MODL-AF)
  • The major goal of this project is to evaluate two promising, novel services that utilize pharmacist and nurse anticoagulation specialists to provide coordinated care to patients taking direct oral anticoagulants. We will determine the optimal approach to efficiently maximize the safety and effectiveness of these medications in the ambulatory setting.

    • Funder: Agency for Healthcare Research and Quality
    • Study End Date: 05/31/2021

  • Direct-to-Patient Outreach to Improve Laboratory Monitoring High-Risk Medications in Ambulatory Care /IVR Lab Outreach
  • The major goal is to further develop and expand an existing QI high-risk medication monitoring IVR outreach program while moving it into KPCO clinical operations.

    • Funder: KPCO Integrated Regional Analytics (IRA)
    • Award End Date: 12/31/2019

  • Reducing Risk through Technology-Enabled Direct-to-Patient Reminders to Obtain Safety Testing for High-Risk Medications
  • This project builds on previous successful high-risk medication laboratory monitoring projects to further reduce risk by expanding technology-enabled direct-to-patient diagnostic laboratory testing and procedure reminders to additional high-risk medications with recommended safety testing and by evaluating the effectiveness of these reminders in additional populations.

    • Funder: Lokahi Risk Management
    • Study End Date: 12/31/2019

  • A Team-Based and Technology Driven Adherence Intervention to Improve Chronic Disease Outcomes
  • This project will identify patients with primary and secondary nonadherence and apply a coordinated team outreach and care approach to help patients achieve evidence-based personalized glucose, blood pressure, or lipids goals.

    • Funder: National Heart, Lung, and Blood Institute
    • Study End Date: 08/31/2022

  • Sentinel 2014
  • The Sentinel System is a national electronic active surveillance system that greatly enhances the ability of the FDA to track the safety of FDA-regulated drugs, biologics, and medical devices.

    • Funder: U.S. Food & Drug Administration
    • Study End Date: 9/21/2019

  • Using a Medical Data Warehouse (MDW) to assess Laboratory Quality Improvement Outcomes
  • The purpose of this study is to demonstrate how healthcare data in a MDW enables evaluation of a laboratory medicine QI initiative. Outcomes are: Raised awareness 1) that MDWs can be used to identify & address laboratory quality gaps and 2) of a specific QI intervention to improve patient and/or system outcomes.

    • Funder: Centers for Disease Control & Prevention
    • Study End Date: 8/31/2019

  • Evaluation of the Risk of Neural Tube Defects Among Live Births Exposed to Maternal Prescription Opioids During Early Pregnancy
  • The goal of this study is to study the association between opioid use during early gestation and primary neural tube defects.

    • Funder: National Heart, Lung, & Blood Institute
    • Award End Date: 9/28/2019

  • Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP)
    • Funder: U.S. Food & Drug Administration
    • Award End Date: 09/14/2021